USFDA concludes inspection at Emcure Pharma Gujarat facility without any observation
- byDoctor News Daily Team
- 11 October, 2025
- 0 Comments
- 0 Mins

Pune:Emcure Pharmahas announced that the United States Food and Drug Administration (US FDA) hasconcluded an inspection at the Company’s Gujarat manufacturing facility without any observation. The surveillance inspection was conducted from October 06, 2025 to October 10, 2025. "This is to inform you that the United States Food and Drug Administration (“US FDA”) had conducted surveillance inspection of Company’s manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, District- Surendranagar, Gujarat - 382775, from October 06, 2025 to October 10, 2025," Emcure stated in a BSE filing. Read also:Emcure Pharma Gets CDSCO Panel Nod for Phase III Trial of Semaglutide in Chronic Weight Management Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada. Read also:Emcure Pharma Ahmedabad oncology facility concludes USFDA inspection with no observations
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
AbbVie concludes acquisition of Gilgamesh Pharma B...
- 21 October, 2025
Dr Soumya Swaminathan conferred Honorary Doctorate...
- 21 October, 2025
Bengaluru Dermatologist Sent to Judicial Custody A...
- 21 October, 2025
NMC approval to 110 PG medical seats in JnK
- 21 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!